Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors.

Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. Curr Opin Organ Transplant. 2019 Jun;24(3):351-357 Authors: Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT Abstract PURPOSE OF REVIEW: Owing to long waitlist times and high waitlist morbidity and mortality, strategies to increase utilization of hepatitis C viremic-deceased donor organs are under investigation in kidney, liver, heart, and lung transplantation. RECENT FINDINGS: Direct-acting antiviral medications for hepatitis C virus infection have high cure rates and are well tolerated. Small, single-center trials in kidney and heart transplant recipients have demonstrated that with early posttransplant direct-acting antiviral therapy, 100% of uninfected recipients of hepatitis C viremic organs have been cured of infection after transplantation. SUMMARY: In this manuscript, we review the risks and rewards of utilizing hepatitis C viremic organs for transplantation. PMID: 31090648 [PubMed - in process]
Source: Current Opinion in Organ Transplantation - Category: Transplant Surgery Authors: Tags: Curr Opin Organ Transplant Source Type: research